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Introduction
Patients with obstructive sleep apnea syndrome (OSAS) often experience diurnal as well as nocturnal hypertension, with OSAS being recognized as a strong risk factor for cardiovascular morbidity and mortality (1) (2) (3) (4) (5) . The repeated episodes of both arousal from sleep and hypoxia as well as the futile respiratory effort due to upper airway obstruction in OSAS patients result in stimulation of the sympathetic nervous system and may adversely affect hemodynamics (6) (7) (8) . Indeed, the autonomic responses to sleep apnea or hypopnea likely contribute to both the acute and chronic cardiovascular consequences of OSAS. We previously showed that repeated episodes of end-apneic arousal or hypoxia and consequent sleep fragmentation are associated with an increase in nocturnal blood pressure that can lead to sustained hypertension and left ventricular hypertrophy (9) (10) (11) . Both hypertension and left ventricular hypertrophy are strong cardiovascular risk factors (12) and are associated with poor prognosis in patients with OSAS (13) . However, the mechanisms by which recurrent nocturnal surges in blood pressure and sympathetic activity in OSAS patients lead to cardiovascular disease or abnormal autonomic control of the heart during the daytime are unclear.
Changes in the function of the cardiac autonomic nervous system are a powerful predictor of cardiac death in patients with cardiac disease (14, 15) , but little is known of the mechanisms by which this system is regulated. Recent studies have suggested that nitric oxide (NO) may play an important role in such regulation. Evidence indicates that NO may attenuate cardiovascular end-organ responses to sympathetic stimulation (16) . In addition, central attenuation by NO of baroreflex-mediated vagal control has been described (16, 17) . OSAS patients experience endothelial dysfunction, a subclinical condition that is associated with atherosclerosis and which manifests both as an abnormal arterial reactivity to NO-dependent vasodilators (18) and as a reduced plasma level of NO in the morning (19) .
In the present work, we investigated the relations of daytime baroreflex sensitivity (BRS) and the plasma level of NO to the severity of OSAS. We have also examined the effects of nocturnal therapy with continuous positive airway pressure (CPAP) both on baroreflex function during the daytime and on the plasma level of NO in patients with moderate to severe OSAS.
Methods Subjects
Fifty-one consecutive male patients with OSAS, aged 28 to 71 years (mean±SD, 53.4±10.0 years), and 29 age-matched healthy males without OSAS (50.1±11.3 years) were included in the study. None of the subjects had diabetes mellitus, chronic obstructive lung disease, coronary or valvular heart disease, congestive heart failure, renal failure, or endocrine dysfunction. Moreover, none of them were taking antihypertensive agents at the time of enrollment in the study. The OSAS patients were divided into two subgroups: those with an apnea-hypopnea index (AHI) of ≥ 20 episodes per hour (n= 40), and those with an AHI of < 20/h (n= 11). The control group was recruited from healthy males aged 40 to 60 years who were free from medication and had no history of cardiovascular disease or diabetes mellitus. The electrocardiograms, echocardiographic findings, and blood pressure of the control subjects were normal. The study protocol was approved by the appropriate institutional review committee, and subjects provided written consent to participation after being informed in detail of the purpose and methods of the study.
Sleep Analysis
All subjects underwent standard polysomnography (Alice III instrument; Respironics, Murrysville, USA) with pulse oximetry. Apnea, hypopnea, sleep stages, and electroencephalographic arousal were scored according to established criteria (20) (21) (22) . OSAS was diagnosed when the AHI was ≥ 5/h (20) .
After the initial polysomnographic evaluation, OSAS patients with an AHI of ≥ 20/h, who have a poorer outcome compared with those with an AHI of < 20/h (23), were randomized into groups that received CPAP (Respironics) for 3 months (CPAP group, n= 21) or did not receive such treatment (non-CPAP group, n= 19). During the 3-month treatment period, seven patients discontinued CPAP (five received treatment with an oral appliance and two underwent conventional tonsillectomy), with the result that 19 patients in the non-CPAP group and 14 patients in the CPAP group completed the trial. Six patients in the non-CPAP group were prescribed calcium antagonists during the 3-month treatment period.
On the night after the baseline sleep analysis, those patients assigned to receive CPAP underwent overnight titration of the pressure to adjust it so as either to abolish apnea, hypopnea, and oxygen desaturation or to determine the highest level tolerated. Urine samples were obtained on the two consecutive days involving overnight sleep analysis (both before and during treatment with CPAP), and 24-h urinary catecholamine excretion was measured. We also assessed the effects of CPAP treatment on pulse wave velocity (PWV) and plasma NO concentration. The concentration of NO in plasma was measured by a colorimetric method (Nitrate/Nitrite Colorimetric Assay Kit; Cayman Chemical, Ann Arbor, USA) that detects NO, NO2
− , and NO3 − (together designated NOx) (24) .
Plasma NOx was measured in the early morning on the days before and after the first night of CPAP treatment, and brachial-ankle PWV was measured with a volume-plethysmographic apparatus (PWV/ABI; Nihon Colin, Komaki, Japan) before and after 3 months of CPAP treatment. Patients in the CPAP group were sent home with a pressure device and instructed to use it for at least 4 h per night on at least 70% of nights. The patients visited their hospitals once a month, and compliance with the pressure treatment protocol was assessed each month from each individual's recorded usage of the pressure device.
Cardiovascular Autonomic Tests
The cardiovascular autonomic response of all subjects was evaluated with the Valsalva test (25) , which was repeated in patients in the CPAP and non-CPAP groups after the 3-month treatment period. Beat-to-beat arterial blood pressure was measured noninvasively with a tonometric device (BP-508SP; Nihon Colin). With the subjects sitting upright and their nasal airflow stopped with a clip, the tonometric sensor was positioned on the radial artery at the same height as the heart. The subjects performed the Valsalva test by expiring into a rubber tube connected to a mouthpiece and maintaining a pressure of 40 mmHg, as revealed by a mercury manometer, for 10 s. Both blood pressure and the R-R interval on the electrocardiogram were continuously recorded until the hemodynamics of the subject had stabilized under the control condition. The BRS index (BRSI), defined as the slope of the linear relation between systolic blood pressure and the R-R interval on the electrocardiogram, was determined during the forced expiration and release (overshoot) phases (phases II and IV, respectively) of the Valsalva maneuver. We also calculated the ratio of the longest R-R interval in phase IV and the shortest R-R interval in phase II (Valsalva ratio). A regression line with a correlation coefficient of > 0.8 and with a blood pressure change of > 15 mmHg was used for analysis (26) .
Statistical Analysis
Data are presented as the means±SD and were analyzed by analysis of variance followed by Scheffe's test. Parameters at baseline and after treatment with CPAP were compared with Student's paired t-test. Correlations were assessed by simple regression analysis and multiple regression analysis based on a stepwise forward selection method. All analyses were performed with the SPSS 12.0 software package (SPSS, Chicago, USA). A p value of < 0.05 was considered statistically significant. 
Results
The BRSI for phase IV of the Valsalva maneuver and plasma concentration of NOx were significantly lower, whereas the AHI, oxygen desaturation time, arousal index, percentage of time spent in sleep stage 1, and systolic blood pressure were significantly greater, in OSAS patients with an AHI of ≥ 20/h than in control subjects or in patients with an AHI of < 20/h ( Table 1 ). The BRSI for phase IV of the Valsalva maneuver, Valsalva ratio, plasma concentration of NOx, and the percentage of time spent in sleep stages 3 + 4 were significantly lower, whereas diastolic blood pressure was significantly greater, in patients with an AHI of ≥ 20/h or in those with an AHI of < 20/h than in control subjects. The percentages of time spent in sleep stage 1, sleep stage 2, or rapid eye movement (REM) sleep did not differ significantly between patients with an AHI of < 20/h and controls. In patients with OSAS, the Valsalva ratio was significantly correlated with the AHI (r= −0.45, p< 0.001), oxygen desaturation time (r= −0.49, p< 0.0005), and the arousal index (r= −0.57, p< 0.0001), whereas the BRSI for phase IV was correlated with oxygen desaturation time (r= −0.37, p< 0.01) and the arousal index (r= −0.37, p< 0.01) but not with the AHI. Multiple regression analysis, including the AHI, oxygen desaturation time, the arousal index, age, and systolic and diastolic blood pressures, revealed that oxygen desaturation time and the arousal index were the most significant contributing factors to the decreased BRSI for phase IV and the decreased Valsalva ratio, respectively, in OSAS patients (Table 2) .
There were no significant differences in baseline sleep parameters or BRS values between the CPAP and non-CPAP groups. The percentages of sleep stage 1 and REM sleep were significantly decreased and increased, respectively, and the 24-h urinary excretion of norepinephrine was significantly reduced by treatment of OSAS patients with CPAP (Table 3 ; Fig. 1 ). The plasma concentration of NOx was also significantly increased after one night of CPAP treatment (Fig. 1) . Both the BRSI for phase IV and the Valsalva ratio were significantly increased, whereas systolic blood pressure and PWV were significantly decreased, in the CPAP group after the 3-month treatment period (Fig. 2) . In contrast, these parameters remained unchanged in the non-CPAP group.
Discussion
We have shown that 1) the BRSI and plasma concentration of NOx were significantly reduced in OSAS patients with an AHI of ≥ 20/h compared with those in healthy controls or in patients with an AHI of < 20/h, whereas the Valsalva ratio was significantly lower in patients with an AHI of ≥ 20/h and in those with an AHI of < 20/h than in control subjects; 2) the BRSI in OSAS patients was inversely related to the severity of sleep fragmentation and hypoxia; and 3) successful treatment of OSAS with CPAP was accompanied by an increase in both the BRSI and plasma NOx concentration as well as by a decrease in 24-h urinary norepinephrine excretion. Our results suggest that a reduced BRSI and decreased NO production, possibly together with an increase in sympathetic activity, might play a role in the pathogenesis of cardiovascular complications in patients with OSAS.
Cardiovascular Autonomic Control in OSAS
We have now demonstrated a correlation between the severity of OSAS and the BRSI. In healthy individuals, sympathetic activity and average blood pressure are reduced during sleep compared with those apparent during wakefulness (9, 27) . In patients with severe OSAS, however, these physiological changes do not occur. Moreover, such patients manifest increased blood pressure and sympathetic activity during wakefulness compared with healthy subjects (8, 28) . Clinical observations have linked sleep-disordered breathing, a condition characterized by repeated arousal and arterial oxygen desaturation, with hypertension (29) . The reduction in the BRSI in OSAS patients may contribute to a further increase in blood pressure, leading to a vicious cycle that may have adverse clinical implications for the development of cardiovascular complications (30, 31) . The slope of the relation between heart period and arterial pressure has been shown to be similar when arterial pressure is increased pharmacologically (with phenylephrine) or physiologically (during phase IV of the Valsalva maneuver) (32, 33) . Given that a reduced BRS is a marker of high cardiovascular risk in several clinical conditions, including myocardial infarction (15) and congestive heart failure (14, 34) , our findings may explain the increased risk of cardiovascular complications in patients with OSAS.
Our present data show that oxygen desaturation time was inversely related to the Valsalva ratio in OSAS patients. This finding is similar to the results of our previous spectral analysis of heart rate variability on 24-h electrocardiograms recorded from OSAS patients (35) . A reduction in heart rate variability in normotensive subjects has been shown to predict subsequent development of hypertension (36) . The increase in blood pressure during phase IV of the Valsalva test stimulates baroreceptors, resulting in a reflex bradycardia secondary to an increased parasympathetic activity, all of which effects are abolished by administration of atropine (37) . An altered parasympathetic activity may play a role in the development of cardiovascular disease, such as through daytime hypertension, in patients with OSAS (38) (39) (40) .
Effect of CPAP Treatment on the BRSI in OSAS Patients
Treatment of OSAS patients with CPAP resulted in an increase in the daytime BRSI in addition to an improvement in sleep quality, normalization of nocturnal oxygenation, an increase in plasma NOx concentration, and a decrease in 24-h urinary norepinephrine excretion. Acute application of CPAP (42) . Although the effects of CPAP on autonomic and cardiovascular alterations remain controversial, evidence suggests that appropriate CPAP treatment for OSAS ameliorates sympathetic hyperactivity as well as tonic activation of peripheral chemoreceptors and hyperresponsiveness to hypoxia (43) (44) (45) .
The BRSI and plasma concentration of NOx were significantly greater in control subjects or in patients with an AHI of < 20/h than in patients with an AHI of ≥ 20/h. The increased sympathetic activity during sleep in patients with OSAS appears to carry over into the daytime (26) . Increased sympathetic drive during wakefulness and repetitive surges in blood pressure during sleep may reduce BRS or reset the baroreflex function curve to higher levels of pressure (40, 46) . The reversible resetting and change in BRS associated with sleep are likely centrally mediated (47) . NO plays a key role in regulation of vascular tone, the impairment of which is associated with the development of various pathological conditions such as hypertension and diabetes mellitus (48) (49) (50) (51) . NO is also implicated in the regulation of sympathetic outflow in the central nervous system (33) . General inhibition of central NO synthesis or inhibition of NO synthesis in regions that are involved in modulation of sympathetic nerve activity results in increases in both arterial pressure and sympathetic outflow (33, 52, 53) . NO may also act as an important mediator of cardiovascular autonomic control in OSAS (16, 17) . Furthermore, altered NO-mediated mechanisms in peripheral tissues and in the brain may contribute to the pathophysiology of several disease states, including heart failure (54-56). Our findings thus suggest that the BRSI of OSAS patients might be altered by sleep apnea itself or by such consequences as hypoxemia, sleep fragmentation, exaggerated sympathetic activity, a decreased plasma NOx level, and increased catecholamine secretion. All of these sequelae may result in an impairment of baroreflex and cardiovascular reflex functions that carries over into the daytime. We have now shown that the blunted BRSI during the daytime in patients with moderate to severe OSAS is treatable by nocturnal CPAP.
Study Limitations
Six patients in the non-CPAP group were prescribed calcium antagonists and seven patients discontinued CPAP during the 3-month treatment period. The remaining randomized population of 33 OSAS patients in whom the effects of CPAP were evaluated in the present study may thus be somewhat biased. The effects of CPAP described in our study thus require verification with a large-scale placebo-controlled study.
Conclusions
We conclude that the daytime BRSI and NO production are impaired as a result of nocturnal oxygen desaturation, sleep fragmentation, and increased sympathetic activity in patients with moderate to severe OSAS. The alterations in the function of the cardiac autonomic nervous system and endothelial dysfunction likely contribute to the increased risk for cardiovascular morbidity and mortality in OSAS patients and are ameliorated by successful long-term treatment with CPAP.
